论文部分内容阅读
目的探讨父供子的单倍体造血干细胞移植疗效。方法 25例恶性血液病男性患者行父亲为供者的单倍体造血干细胞移植,观察患者的造血重建时间、移植物抗宿主病(GVHD)的发生率、复发率、2年总生存率及2年无病生存率。结果(1)25例患者均获得完全植入。患者中性粒细胞≥0.5×10~9/L植入的中位时间为15 d(12~17 d),植入血小板≥20×10~9/L的中位时间为17 d(9~40 d)。(2)25例中有10例患者发生急性GVHD,发生率40.0%,其中2例患者Ⅲ度肠道、肝脏急性GVHD。移植后持续随访100 d,慢性GVHD的患者7例,发生率28.0%,其中广泛型3例。(3)随访至2014年6月,父亲供儿子移植组中原发病复发2例(8.0%)。父亲供儿子移植组中16例无病存活,9例死亡,移植相关死亡率为28.0%。患者2年总生存率为68.0%,2年无病生存率为68.0%。结论父亲为供者的单倍体造血干细胞移植是一种安全、有效的移植方式。
Objective To investigate the efficacy of paternity donor haploid hematopoietic stem cell transplantation. Methods Twenty-five male patients with hematologic malignancies underwent donor haploid hematopoietic stem cell transplantation. The hematopoietic reconstitution time, graft-versus-host disease (GVHD) incidence, relapse rate, 2-year overall survival rate and 2 Disease-free survival rate. Results (1) 25 patients were completely implanted. The median time for implantation of neutrophils≥0.5 × 10 ~ 9 / L was 15 days (ranged from 12 to 17 days), and the median time for platelet transplants ≥20 × 10 ~ 9 / L was 17 days (range, 40 d). (2) Acute GVHD occurred in 10 of 25 patients, the incidence rate was 40.0%. Two of them had grade Ⅲ intestine and liver acute GVHD. After follow-up of 100 days after transplantation, 7 cases of chronic GVHD patients, the incidence rate of 28.0%, of which 3 cases of extensive type. (3) Follow-up to June 2014, 2 cases (8.0%) relapsed in the father’s sons transplantation group. Sixteen patients died of disease-free survival in the father’s son-transplant group, 9 died, and the transplant-related mortality was 28.0%. The 2-year overall survival rate was 68.0%, and the 2-year disease-free survival rate was 68.0%. Conclusion The haploidentical hematopoietic stem cell transplantation with his father as donor is a safe and effective transplantation method.